Magnolia Capital Advisors LLC Makes New $844,000 Investment in Edwards Lifesciences Corporation $EW

Magnolia Capital Advisors LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 9,328 shares of the medical research company’s stock, valued at approximately $844,000.

A number of other institutional investors also recently modified their holdings of EW. Rehmann Capital Advisory Group grew its stake in shares of Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after acquiring an additional 130 shares in the last quarter. McIlrath & Eck LLC boosted its position in Edwards Lifesciences by 14.6% during the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 135 shares during the last quarter. Quadrant Capital Group LLC increased its position in shares of Edwards Lifesciences by 0.9% during the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after purchasing an additional 136 shares during the last quarter. Stephens Inc. AR boosted its holdings in shares of Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after buying an additional 144 shares during the last quarter. Finally, Composition Wealth LLC raised its position in Edwards Lifesciences by 1.6% during the fourth quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock worth $795,000 after acquiring an additional 147 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. Piper Sandler restated an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Evercore reissued an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Finally, Royal Bank Of Canada increased their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Up 0.1%

Shares of NYSE EW opened at $90.93 on Thursday. The company has a market cap of $52.36 billion, a price-to-earnings ratio of 52.26, a PEG ratio of 2.38 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $89.43 and a two-hundred day moving average price of $84.91. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 2,425 shares of company stock worth $219,199. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.